Combination romidepsin and azacitidine therapy is well tolerated and clinically active in adults with high-risk acute myeloid leukaemia ineligible for intensive chemotherapy.
Br J Haematol
; 196(2): 368-373, 2022 01.
Article
in En
| MEDLINE
| ID: mdl-34490623
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Leukemia, Myeloid, Acute
/
Antineoplastic Combined Chemotherapy Protocols
Type of study:
Etiology_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Adolescent
/
Adult
/
Female
/
Humans
/
Male
Language:
En
Journal:
Br J Haematol
Year:
2022
Type:
Article
Affiliation country:
United kingdom